| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 901 | 2022 |
| Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy EI Patterson, G Elia, A Grassi, A Giordano, C Desario, SL Smith, ... Nature communications 11 (1), 6231, 2020 | 382 | 2020 |
| Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre … CD Russell, CJ Fairfield, TM Drake, L Turtle, RA Seaton, DG Wootton, ... The Lancet Microbe 2 (8), e354-e365, 2021 | 278 | 2021 |
| Methods of inactivation of SARS-CoV-2 for downstream biological assays EI Patterson, T Prince, ER Anderson, A Casas-Sanchez, SL Smith, ... The Journal of infectious diseases 222 (9), 1462-1467, 2020 | 240 | 2020 |
| Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel ER Adams, M Ainsworth, R Anand, MI Andersson, K Auckland, JK Baillie, ... Wellcome Open Research 5, 2020 | 221 | 2020 |
| Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study RK Gupta, EM Harrison, A Ho, AB Docherty, SR Knight, M van Smeden, ... The Lancet Respiratory Medicine 9 (4), 349-359, 2021 | 207 | 2021 |
| Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the … CI Bloom, TM Drake, AB Docherty, BJ Lipworth, SL Johnston, ... The Lancet Respiratory Medicine 9 (7), 699-711, 2021 | 164 | 2021 |
| Lactobacillus reuteri protects epidermal keratinocytes from Staphylococcus aureus-induced cell death by competitive exclusion T Prince, AJ McBain, CA O'Neill Applied and environmental microbiology 78 (15), 5119-5126, 2012 | 148 | 2012 |
| Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study TM Drake, AM Riad, CJ Fairfield, C Egan, SR Knight, R Pius, ... The Lancet 398 (10296), 223-237, 2021 | 142 | 2021 |
| A prenylated dsRNA sensor protects against severe COVID-19 A Wickenhagen, E Sugrue, S Lytras, S Kuchi, M Noerenberg, ML Turnbull, ... Science 374 (6567), eabj3624, 2021 | 141 | 2021 |
| A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19 J Huo, H Mikolajek, A Le Bas, JJ Clark, P Sharma, A Kipar, J Dormon, ... Nature communications 12 (1), 5469, 2021 | 109 | 2021 |
| Evaluation of antibody testing for SARS-Cov-2 using ELISA and lateral flow immunoassays E Adams, M Ainsworth, R Anand, MI Andersson, K Auckland, JK Baillie, ... MedRxiv, 2020 | 101 | 2020 |
| SARS-CoV-2 Omicron-B. 1.1. 529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19 EG Bentley, A Kirby, P Sharma, A Kipar, DF Mega, C Bramwell, ... BioRxiv, 2021.12. 26.474085, 2021 | 96 | 2021 |
| Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK AB Docherty, RH Mulholland, NI Lone, CP Cheyne, D De Angelis, ... The Lancet Respiratory Medicine 9 (7), 773-785, 2021 | 94 | 2021 |
| Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study TM Drake, CJ Fairfield, R Pius, SR Knight, L Norman, M Girvan, ... The Lancet Rheumatology 3 (7), e498-e506, 2021 | 87 | 2021 |
| SARS-CoV-2 infections in animals: reservoirs for reverse zoonosis and models for study T Prince, SL Smith, AD Radford, T Solomon, GL Hughes, EI Patterson Viruses 13 (3), 494, 2021 | 74 | 2021 |
| The impact of viral mutations on recognition by SARS-CoV-2 specific T cells TI de Silva, G Liu, BB Lindsey, D Dong, SC Moore, NS Hsu, D Shah, ... Iscience 24 (11), 2021 | 62 | 2021 |
| SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination F Liew, S Talwar, A Cross, BJ Willett, S Scott, N Logan, MK Siggins, ... EBioMedicine 87, 2023 | 58 | 2023 |
| Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study F Närhi, SR Moonesinghe, SD Shenkin, TM Drake, RH Mulholland, ... The Lancet Digital Health 4 (4), e220-e234, 2022 | 26 | 2022 |
| SARS-CoV-2 neutralising antibodies in dogs and cats in the United Kingdom SL Smith, ER Anderson, C Cansado-Utrilla, T Prince, S Farrell, B Brant, ... Current research in virological science 2, 100011, 2021 | 22 | 2021 |
Grant HughesLiverpool School of Tropical MedicineVerified email at lstmed.ac.uk
